Quantcast

Can-Fite Subsidiary OphthaliX Provides an Update on its Clinical Developments and Strategic Plans

June 9, 2014

- Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded

PETACH TIKVA, Israel, June 9, 2014 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc., has issued an update on its clinical developments and strategic plans:

    --  Glaucoma - OphthaliX is focused on the development of CF101 for the
        treatment of glaucoma, with a Phase II study ongoing in Israel and
        Europe. OphthaliX intends to amend the ongoing Phase II study protocol
        and continue to the second cohort, where patients will be treated with 2
        mg CF101 or placebo. This decision is based on positive data from the
        psoriasis Phase II/III study currently conducted with CF101 by Can-Fite.
        As a result, there will not be an interim analysis and the full study
        data is expected to be announced in mid-2015. If successful, the
        treatment of glaucoma with an oral drug has the potential to be a
        breakthrough treatment in resolving patient compliance issues with
        current topical treatments. A third-party validation for the utilization
        of A3 adenosine receptor agonists for lowering intraocular pressure and
        treating glaucoma has been recently published by Professor M. Francesca
        Cordeiro, a Professor of Glaucoma & Retinal Neuro-degeneration at the
        University College of London and Imperial College in London.
    --  Dry Eye Syndrome - OphthaliX has decided to end the development of CF101
        for the dry eye syndrome indication. This decision is based on a lack of
        correlation between patients' response to CF101 and over-expression of
        the drug target, the A3 adenosine receptor in this patient population.
    --  In-Licensing New Technologies - As part of OphthaliX's corporate
        strategy to build a specialized ophthalmic company that develops and
        in-licenses drugs for the treatment of ophthalmic diseases, OphthaliX is
        currently exploring opportunities to obtain technologies that will
        complement and expand the existing pipeline.

About CF101

CF101, an A3 adenosine receptor (A3AR) agonist, is a novel, first in class small molecule orally bioavailable drug which binds with high affinity and selectivity to the A3AR, which is known to be over-expressed in inflammatory cells. The drug acts as a neuro-protective agent and prevents apoptosis of retinal ganglion cells.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is in Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission (the “SEC”), press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114

SOURCE Can-Fite BioPharma Ltd.


Source: PR Newswire



comments powered by Disqus